Healing Effects of Dried and Acellular Human Amniotic Membrane and Mepitelas for Coverage of Skin Graft Donor Areas; A Randomized Clinical Trial.

Autor:	Nouri M; Department of Regenerative Biomedicine, Cell Science Research Center, Royan Institute, Tehran, Iran., Ebrahimi M; Department of Regenerative Biomedicine, Cell Science Research Center, Royan Institute, Tehran, Iran., Bagheri T; Burn research Center, Iran University of Medical Sciences, Tehran, Iran., Fatemi MJ; Burn research Center, Iran University of Medical Sciences, Tehran, Iran., Najafbeygi A; Department of Plastic Surgery, Hazrat Fatima Hospital, Iran University of Medical Sciences, Tehran, Iran., Araghi S; Hazrat Fatima Hospital, Iran University of Medical Sciences, Tehran, Iran., Molaee M; Hazrat Fatima Hospital, Iran University of Medical Sciences, Tehran, Iran.
Jazyk:	angličtina
Zdroj:	Bulletin of emergency and trauma [Bull Emerg Trauma] 2018 Jul; Vol. 6 (3), pp. 195-200.
DOI:	10.29252/beat-060302
Abstrakt:	Objective: To compare the healing effects of dried and acellular human amniotic membrane and Mepitel for coverage of split-thickness graft donor site (STGDS). Methods: Twenty patients who underwent STGDS regeneration surgery in identical anatomic regions were enrolled in this randomized controlled clinical trial conducted in Hazrate Fatemeh hospital (Iran). Patients were randomly assigned in 3 groups of wound dressing; group A by Mepitel, group B AmiCare (Dried amniotic membrane) and group C OcuReg-A (Acellular amniotic membrane). Re-epithelization rate (healing time), pain sensation, scar formation and infection rate were assessed till complete healing was achieved. Results: Our results showed no significant difference between Amicare, OcuReg-A and Mepitel in the features analyzed by us including: Re-epithelization rate (healing time) P value; 0.573, Pain sensation P value: day 4 th: 0.131, day8 th: 0.93 and day 12 th: 0.365, Scar formation P value>0.05and Infection rate. Conclusion: Our findings confirmed the safety and efficacy of AmiCare (dried amniotic membrane) and OcuReg-A (Acellular amniotic membrane) in treatment of split-thickness donor site in comparison with Mepitel as a standard wound dressing. Trial registration number: IRCT201511118177N12.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu